Albuquerque Journal (10.28.09) - Thursday, November 12, 2009
Olivier Uyttebrouck

Of 652 drivers who were approached at truck stops and agreed to participate, 54 tested HCV-positive, including 36 who reported using IV drugs at least once in their lives. Many had used the drugs in their teens and 20s, said study co-author Dr. Steve Jenison, medical director of the department's infectious-diseases bureau. Only nine drivers, or 1.4 percent of those studied, reporting using IV drugs within the previous year.

Other positive tests results were: hepatitis B anticore (anti- HBc) antibodies, 66 drivers; chlamydia, eight; gonorrhea, one; syphilis, one; and HIV, one.

"Almost all of those we talked to said it had been years or decades since they used injected drugs," Jenison said. "Most said they regretted it and put it behind them."

Jenison and colleagues suggested that trucking firms offer comprehensive health screenings that accommodate the working life of long-haul drivers, who travel an average of 288 days a year. "We talked to the ones that were hepatitis C-positive, and the great majority of them didn't know they had it," Jenison said. "They had never been tested before. It is worthwhile knowing whether you have hepatitis C and knowing whether or not your hep C is moving in the direction of cirrhosis of the liver."

The full report, "Risk Assessment and Screening for Sexually Transmitted Infections, HIV, and Hepatitis Virus Among Long- Distance Truck Drivers in New Mexico, 2004-2006," was published in the American Journal of Public Health (2009;99(11):2063-2068).
091112
AD091943

Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.